Medicinrådet (Medical Council) recommends the drug Enhertu for patients with the HER2-low type of breast cancer

The Medical Council estimates that Enhertu can extend patients’ lives, although it is very uncertain for how long. At the same time, there are more severe side effects with treatment with Enhertu than with the current treatment. The recommendation of Enhertu for HER2-low comes after the pharmaceutical company lowered the price at the request of the Medical Council.